Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
NCT00817063 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG alitretinoin
Study Locations (20)
California
- Shahram Jacobs, MD, Inc. — Encino
- University of California, San Diego Dermatology Clinical Trials Unit — La Jolla
- Dermatology Research Associates — Los Angeles
- Laser and Dermatology Center — Marina del Rey
- Integrated Research Group — Riverside
- University of California, Davis — Sacramento
- Therapeutics Clinical Research — San Diego
- East Bay Psoriasis Treatment Center — San Ramon
- Stanford University Dept of Dermatology — Stanford
- Solano Clinical Research, Dow Pharmaceutical Sciences — Vallejo
Arkansas
- Johnson Dermatology — Fort Smith
- Dermatology Research of Arkansas — Little Rock
- Hull Dermatology — Rogers
Colorado
- Longmont Clinic, P.C. — Longmont
- Western State Clinical Research Inc. — Wheat Ridge
Florida
- Park Avenue Dermatology, PA — Orange Park
- Palm Beach Research Center — West Palm Beach
Alabama
- University of Alabama, Birmingham — Birmingham
Arizona
- Radiant Research Inc. — Tucson
District of Columbia
- George Washington University - Medical Faculty Associates — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2009-01-08 |
| Est. Completion | 2012-04-26 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817063
The ClinicalTrials.gov registry entry for NCT00817063 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 599 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 10 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Eczema appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00817063 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Arkansas, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00817063 about?
NCT00817063 is a clinical study titled "Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema". The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
What is the current status of trial NCT00817063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2009-01-08. Estimated completion is 2012-04-26.
What conditions does trial NCT00817063 study?
This clinical trial studies the following conditions: Eczema. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00817063?
The interventions under investigation include: Placebo (DRUG), alitretinoin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00817063?
This trial is sponsored by Stiefel, a GSK Company, which has 10 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00817063 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.